01488nas a2200325   4500000000100000008004100001260001300042653001200055653001700067653003100084653001400115653001100129653002100140653002300161653001200184653000900196653002900205653001400234653001700248653001300265100001800278700001600296700001800312700001100330245008400341300001000425490000800435520070500443022001401148       1997                            d  c1997 Aug10aAnimals10aCD4 Antigens10aCD8-Positive T-Lymphocytes10aCytokines10aHumans10aImmunity, Active10aImmunity, Cellular10aleprosy10aMice10aMycobacterium Infections10aTh1 Cells10aTuberculosis10aVaccines1 aOttenhoff T H1 aSpierings E1 aNibbering P H1 aJong R00aModulation of protective and pathological immunity in mycobacterial infections.  a400-80 v1133 a<p>Mycobacterial infections represent major problems to global health care. Tuberculosis is feared particularly because of its high mortality rates whereas in leprosy the occurrence of immunopathology, particularly nerve damage, is a major problem since the bacillus itself is relatively harmless. Thus, both effective vaccination strategies as well as novel immunomodulating regimens are warranted for the control of morbidity and mortality in mycobacterial diseases. Since CD4+ Th1 cells and type-1 cytokines play a key role both in protective immunity and immunopathology in mycobacterial infections, we here describe new pharmacological and cytokine-based strategies to regulate Th1 immunity.</p>  a1018-2438